University of Nebraska Medical Center

Apar Kishor Ganti, MD

Professor, UNMC Division of Oncology & Hematology
Associate Director for Clinical Research, Fred & Pamela Buffett Cancer Center
Research Focus: Lung Cancer, Mesothelioma, Thymoma, Head and Neck Cancers, Thyroid Cancers

Apar Ganti, MD

Dr. Ganti is a physician-scientist, who completed his medical training and a residency in Clinical Pharmacology in Pune, India. He subsequently completed an Internal Medicine residency, a Medical Oncology fellowship and a Master’s Program in Clinical and Translational Research.

Dr. Ganti is the Associate Director of Clinical Research at the UNMC Fred and Pamela Buffett Cancer Center. He is a member of the Respiratory Committee of the Alliance for Clinical Trials in Oncology. He is the Chair of the Small Cell Lung Cancer Committee of the National Comprehensive Cancer Network and the VA Clinical Science Research & Development Centralized Data Monitoring Committee.

Dr. Ganti’s research interests are focused on development of novel treatment approaches for patients who are not candidates for standard therapies. His laboratory is focused on identifying novel prognostic and predictive biomarkers for these malignancies.

He has mentored medical students, residents and fellows, and junior faculty in research projects that have been either presented at national or international meetings and/or published in peer reviewed journals.


  • Medical School: B.J. Medical College, University of Pune, India, 1996
  • Residency: Clinical Pharmacology, B.J. Medical College, University of Pune, India, 1999
  • Internship: University of North Dakota School of Medicine, Fargo, 2001
  • Residency: Internal Medicine, University of North Dakota School of Medicine, Fargo, 2003
  • Fellowship: Oncology/Hematology, University of Nebraska Medical Center, 2005
Research Interests

Dr. Ganti's research interests include:

  • Study of the role of MUC5AC mucin in lung adenocarcinoma brain metastases
  • Design of clinical trials for lung cancer patients using novel approaches.
  • Using mobile applications for patient-reported outcomes in lung cancer.
  • Studying the role of IGF1R in small cell lung cancer.